What I remember is that it was Bob Apple that stated, the deal with Pfizer would be disclosed (or discovered) via a filing by Pfizer of a clinical trial. And I recall he said something like, to paraphrase, "probably someone will be find it on clinical trials . gov.
And I just found some notes from the June 6, 2012 Jefferies Conference, see bold faced bullet point below:
"These are my notes from the Jefferies Global Healthcare Conference.
These are specific to slide 7, “Diverse and Advanced Product Pipeline” and what CEO Wotton said of each.
• Three lauched and marketed products (as we all know), TevTropin/Zomajet, Elestrin with Jazz and Gelnique 3% with Watson (US) Daewoong (SK)
• TEVA/VIBEX EPI – launch June 22, 2015
• TEVA/VIBEX 2, filed ANDA – Paul did not mention a specific update other than in reference to the two TEVA pens with filed ANDA's.
• Antares Vibex MTX – NDA to be filed in next 9 months or so, recruiting is ahead of schedule!
• Antares Vibex QS T – a once weekly dose to compete with the gels.
• TEVA Pen 1 – ANDA to be filed in the U.S. by TEVA in 4th Q 2012 – a paragraph 4 filing
• TEVA Pen 2 – a 505b2 U.S. filing, most likely will be filed in Europe ahead of U.S. given the more refined pathway to the market
• Population Council NestraGel – looking for potential partnering opportunity right now.
• Pfizer (undisclosed) – a product going into Ph3 later this year and product will be unveiled when filed on clinicaltrials.gov, but its actually a significant opportunity.
[url][/url][tag]insert-text-here[/tag]
Regarding Paul’s commentary to the two TEVA Pens (1&2), he stated the following:
These are multi dose pens. These pens are typically carried around for like a month and patients such as diabetics use them to inject their medication every day.
Regarding Antares' two proprietary programs, MTX and QST, he stated, 'our own programs, this is where the value, I think, for the company in the future is going to be.'
There was no Q&A session at the end as there was a 'breakout session planned in advance."
Jab9
